当前位置:首页 - 行情中心 - 德源药业(920735) - 财务分析 - 现金流量表

德源药业

(920735)

  

流通市值:29.01亿  总市值:32.80亿
流通股本:1.14亿   总股本:1.29亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金558,550,168.2277,324,279.171,063,419,134.48780,182,348.6
  收到的税费返还17,754.24-3,244,477.673,244,477.67
  收到其他与经营活动有关的现金9,366,834.068,220,622.2131,372,329.2626,758,997.19
  经营活动现金流入小计567,934,756.5285,544,901.381,098,035,941.41810,185,823.46
  购买商品、接受劳务支付的现金78,133,792.8934,951,153.96149,673,660.59109,882,690.97
  支付给职工以及为职工支付的现金109,553,869.360,812,279.36182,915,721.96139,396,996.11
  支付的各项税费84,649,186.8945,171,988.52142,858,246.9106,260,030.96
  支付其他与经营活动有关的现金228,451,228.57109,782,445.74465,921,228.07345,626,363.19
  经营活动现金流出小计500,788,077.65250,717,867.58941,368,857.52701,166,081.23
  经营活动产生的现金流量净额67,146,678.8534,827,033.8156,667,083.89109,019,742.23
二、投资活动产生的现金流量:
  取得投资收益收到的现金4,681,247.211,442,878.735,765,411.674,311,102.79
  处置固定资产、无形资产和其他长期资产收回的现金净额46,088-9,856.318,612
  收到的其他与投资活动有关的现金660,272,416.67280,000,0001,860,600,0001,402,600,000
  投资活动现金流入小计664,999,751.88281,442,878.731,866,375,267.981,406,919,714.79
  购建固定资产、无形资产和其他长期资产支付的现金25,507,362.566,871,388.1853,224,934.5127,448,617.81
  支付其他与投资活动有关的现金638,952,416.67270,952,416.672,121,120,7501,661,120,750
  投资活动现金流出小计664,459,779.23277,823,804.852,174,345,684.511,688,569,367.81
  投资活动产生的现金流量净额539,972.653,619,073.88-307,970,416.53-281,649,653.02
三、筹资活动产生的现金流量:
  取得借款收到的现金1,587,500245,0008,790,000-
  收到其他与筹资活动有关的现金2,664,888.38---
  筹资活动现金流入平衡项目000-
  筹资活动现金流入小计4,252,388.38245,0008,790,000-
  偿还债务支付的现金--27,090,00027,090,000
  分配股利、利润或偿付利息支付的现金47,038,145.251,705.0836,378,914.7936,369,020.63
  支付其他与筹资活动有关的现金626,251594,450901,404901,404
  筹资活动现金流出小计47,664,396.2646,155.0864,370,318.7964,360,424.63
  筹资活动产生的现金流量净额-43,412,007.82-401,155.08-55,580,318.79-64,360,424.63
五、现金及现金等价物净增加额24,274,643.6838,044,952.6-206,883,651.43-236,990,335.42
  加:期初现金及现金等价物余额97,094,952.8697,094,952.86303,978,604.29303,978,604.29
  期末现金及现金等价物余额121,369,596.54135,139,905.4697,094,952.8666,988,268.87
补充资料:
  净利润128,659,223.95-236,929,075.58-
  资产减值准备1,485,009.12-4,023,580.81-
  固定资产和投资性房地产折旧23,107,420.55-25,815,556.91-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧23,107,420.55-25,815,556.91-
  无形资产摊销762,446.76-1,524,893.52-
  长期待摊费用摊销125,280.36-284,609.38-
  处置固定资产、无形资产和其他长期资产的损失41,685.14-26,532.78-
  固定资产报废损失15.04-106,520.03-
  公允价值变动损失-765,534.25--720,457.53-
  财务费用166,635.71-421,903.12-
  投资损失-3,981,779.37--8,269,312.65-
  递延所得税-957,793.6--2,786,367.95-
  其中:递延所得税资产减少-1,204,815.56--2,640,546.07-
    递延所得税负债增加247,021.96--145,821.88-
  存货的减少-24,593,008.64--16,807,802.23-
  经营性应收项目的减少-109,886,499.06--132,502,292.03-
  经营性应付项目的增加50,548,737.8-47,677,864.34-
  现金的期末余额121,369,596.54-97,094,952.86-
  减:现金的期初余额97,094,952.86-303,978,604.29-
  现金及现金等价物的净增加额24,274,643.68--206,883,651.43-
公告日期2026-08-252026-04-282026-03-052025-10-30
审计意见(境内)标准无保留意见
TOP↑